159305-16-5

Usage

Uses

Used in Pharmaceutical Industry:
1H-Indazole,6-fluoro-3-methyl-(9CI) is used as a drug candidate for its potential antibacterial, antifungal, and cytostatic properties. The presence of the fluorine atom may improve the compound's biological activity, making it a valuable asset in the development of new medications.
Used in Agrochemical Industry:
In the agrochemical sector, 1H-Indazole,6-fluoro-3-methyl-(9CI) is utilized for its potential to exhibit pesticidal properties, leveraging its biological activities to control or prevent the growth of unwanted organisms in agricultural settings.
Used in Medicinal Chemistry Research:
1H-Indazole,6-fluoro-3-methyl-(9CI) serves as a building block in the synthesis of other bioactive molecules, contributing to the advancement of medicinal chemistry by providing a structural foundation for the creation of new compounds with therapeutic potential.
Used in Chemical Synthesis:
1H-Indazole,6-fluoro-3-methyl-(9CI) is also used in chemical synthesis processes, where its unique structure and properties can be exploited to produce a variety of chemical entities with specific applications in different fields.

Upstream product

• 159305-15-4 1-(2-Amino-4-fluorophenyl)ethanone 
• 1979-36-8 2',5'-difluoroacetophenone 
• 364-83-0 2',4'-difluoroacetophenone 

Downstream Products

• 174180-43-9 6-Fluoro-3-methyl-indazole-1-carboxylic acid tert-butyl ester 
• 1026677-37-1 6-Fluoro-3-(1-{[isopropyl-(4-methoxy-phenyl)-carbamoyl]-methyl}-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-ylmethyl)-indazole-1-carboxylic acid tert-butyl ester 
• 174180-95-1 tert-butyl 3-(bromomethyl)-6-fluoro-1H-indazole-1-carboxylate 

Relevant academic research and scientific papers

TRIAZINE COMPOUND AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF

The invention discloses a triazine derivative and a pharmaceutically acceptable salt, a pharmaceutical composition and use thereof. Particularly, the invention discloses a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3 and R4 are defined as described in the description and claims. The compound or a salt thereof according to the invention may be used for treating or preventing diseases or conditions by regulating some mutation forms of epidermal growth factor receptors. The invention also discloses a pharmaceutical composition comprising the compound or a salt thereof, and a method for treating various forms of EGFR-mediated diseases (including non-small cell lung cancer) by using the compound and a salt thereof.

INDAZOLE AND AZAINDAZOLE COMPOUNDS AS IRAK-4 INHIBITORS

The present invention provides indazole and aza indazole compounds of formula (I) or (II) and pharmaceutically acceptable salts thereof, and their use to inhibit IRAK-4 and/or for the treatment of diseases or disorders induced by IRAK-4.

Indazole Compounds as IRAK4 Inhibitors

The present invention provides indazole compounds of formula (I), which are therapeutically useful as kinase inhibitors, particularly IRAK4 inhibitors, wherein Z1, Z2, R1, R2, R3, ‘m’ and ‘n’ have the meanings given in the specification, and pharmaceutically acceptable salts or stereoisomers thereof that are useful in the treatment and prevention of diseases or disorders, in particular their use in diseases or disorders mediated by kinase enzyme, particularly IRAK4 enzyme. The present invention also provides pharmaceutical compositions comprising at least one of the compounds of the compound of formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient.

INDAZOLE COMPOUNDS AS IRAK4 INHIBITORS

The present invention provides indazole compound of formula (I), which are therapeutically useful as kinase inhibitor, particularly IRAK4 inhibitors. wherein Z1, Z2, R1, R2, R3, 'm' and 'n' have the meanings given in the specification, and pharmaceutically acceptable salts or stereoisomers thereof that are useful in the treatment and prevention of diseases or disorder, in particular their use in diseases or disorder mediated by kinase enzyme, particularly IRAK4 enzyme. The present invention also provides pharmaceutical composition comprising at least one of the compounds of compound of formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

Antipsychotic indazole derivatives

Disclosed is a class of 1H-indazole derivatives, substituted at the 3-position by a substituted piperazinylmethyl moiety, which are antagonists of dopamine receptor subtypes within the brain, having a selective affinity for the dopamine D4 receptor subtyp

Indazole derivatives

A class of chemical compounds comprising a 1-H-indazole moiety and a substituted heterocyclic moiety, linked via the 3-position of the indazole moiety by a methylene group, are ligands for dopamine receptor subtypes within the body and are therefore usefu